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Clopidogrel Versus Ticlopidine After
the Placement of Coronary Artery Stents
In a study published recently in JACC, Mueller et al. (1) compared
treatment with clopidogrel and aspirin to ticlopidine and aspirin in
patients undergoing coronary stent placement. Both drugs were
started after the procedure and continued for four weeks. Ticlo-
pidine was given as a 500-mg loading dose followed by 250 mg
twice daily thereafter; however, clopidogrel was given without
loading: 75 mg daily. The results suggested that clopidogrel was
inferior to ticlopidine in terms of cardiovascular mortality. In other
studies involving clopidogrel, a loading dose of 300 mg was given
initially followed by 75 mg daily thereafter (2,3). A loading dose of
300 mg of clopidogrel is needed in order to achieve timely platelet
inhibitory effect (4). The lack of clopidogrel loading clearly delays
the effect of clopidogrel and, therefore, may cause a higher
thrombotic stent occlusion (TSO) rate (the TSO rate was not
reported by Mueller et al.). Use of a clopidogrel loading dose in
this instance may show clopidogrel not to be inferior to ticlopidine
(3).
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We fully agree with Dr. Rott that the lack of a loading dose of
clopidogrel is an important issue in interpreting our data. After
completion of our study, two major clinical trials, Clopidogrel for
the Reduction of Events During Observation (CREDO) (1) and
ISAR-REACT (2), were reported that highlight the need for a
loading dose of clopidogrel. In CREDO, the best clinical outcome
was seen in those patients who achieved the full antiplatelet effect
of clopidogrel at the time of intervention, which was 6 h after a
loading dose of 300 mg. Based on clinical observations (3) and ex
vivo analysis of platelet function (4), the ISAR-REACT trial used
an even higher loading dose of clopidogrel, 600 mg, which enables
the full antiplatelet effect of clopidogrel within 2 h (4). With this
loading scheme, the antithrombotic efficacy in patients undergoing
elective interventions could not be further improved even with
abciximab, as shown by the composite 30-day end point of death,
myocardial infarction, and urgent revascularization (2).
In light of these new findings, we cannot exclude that the results
of our trial, as well as those of other trials suggesting inferiority of
clopidogrel compared with ticlopidine (5), would have been
different had an appropriate loading dose been used. Notably, a
high loading dose may overcome the other potential explanation of
our findings, which is the interference of statins. Although the
issue has not been completely settled, preliminary reports indicate
that attenuation of the antiplatelet effect by statins is not detectable
after a 600-mg loading dose (6).
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